- Grifols will be the exclusive supplier of Antithrombin III (AT-III) for treatment of Sepsis, a life-threatening medical emergency
- Endpoint Health expects to submit its Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase II clinical trial of Grifols' Antithrombin III in Sepsis later this year
- Upon FDA approval, the companies will invest to expand existing Antithrombin III production capabilities at Grifols sites
- Grifols strengthens its plasma economics as part of its commitment to drive sustainable growth through innovation
PR Newswire
BARCELONA, Spain, Feb. 24, 2022
